Childhood Non-Hodgkin's Lymphoma: The Results of a Randomized Therapeutic Trial Comparing a 4-Drug Regimen (Comp) with a 10-Drug Regimen (Lsa2-L2)

James R. Anderson, John F. Wilson, R. Derek T. Jenkin, Anna T. Meadows, John Kersey, Robert R. Chilcote, Peter Coccia, Philip Exelby, Joseph Kushner, Stuart Siegel, Denman Hammond

Research output: Contribution to journalArticle

248 Citations (Scopus)

Abstract

Members of the Childrens Cancer Study Group treated 234 eligible patients in a randomized trial designed to study the relative effectiveness of two therapy programs for the treatment of childhood and adolescent non-Hodgkin's lymphoma. Two chemotherapeutic strategies were compared: a 4-drug regimen (COMP) and a 10-drug regimen (modified LSA2-L2). Failure-free survival for all patients was 60 per cent at 24 months. In patients with disseminated disease treatment success was influenced by both the histologic subtype of disease and the therapeutic regimen followed. The 10-drug program was more effective than the 4-drug program in patients with disseminated lymphoblastic disease (two-year failure-free survival rate, 76 vs. 26 per cent, respectively; P = 0.0002), whereas the 4-drug program was more effective than the 10-drug program in those with nonlymphoblastic disease (57 vs. 28 per cent, respectively, P = 0.008). The less toxic, more easily administered 4-drug regimen was as effective as the 10-drug regimen in patients with localized disease (89 vs. 84 per cent, respectively). (N Engl J Med. 1983; 308:559–65.) Considerable progress was made during the 1960s in the treatment of some pediatric cancers — most notably, Wilms' tumor and acute lymphoblastic leukemia. This was not true for the non-Hodgkin's lymphomas of childhood. During the 1960s, only 15 per cent of children with non-Hodgkin's lymphoma could be expected to survive longer than two years.1 The first indications that the use of multiagent therapy could control disease over the long term came from Djerassi and Kim, who obtained promising results with intravenous methotrexate combined with other agents2; from Ziegler, who reported long-term disease control in both American and African patients.

Original languageEnglish (US)
Pages (from-to)559-565
Number of pages7
JournalNew England Journal of Medicine
Volume308
Issue number10
DOIs
StatePublished - Mar 10 1983

Fingerprint

Non-Hodgkin's Lymphoma
Pharmaceutical Preparations
Therapeutics
Wilms Tumor
Poisons
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Methotrexate
African Americans
Neoplasms
Survival Rate
Pediatrics
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Childhood Non-Hodgkin's Lymphoma : The Results of a Randomized Therapeutic Trial Comparing a 4-Drug Regimen (Comp) with a 10-Drug Regimen (Lsa2-L2). / Anderson, James R.; Wilson, John F.; Jenkin, R. Derek T.; Meadows, Anna T.; Kersey, John; Chilcote, Robert R.; Coccia, Peter; Exelby, Philip; Kushner, Joseph; Siegel, Stuart; Hammond, Denman.

In: New England Journal of Medicine, Vol. 308, No. 10, 10.03.1983, p. 559-565.

Research output: Contribution to journalArticle

Anderson, JR, Wilson, JF, Jenkin, RDT, Meadows, AT, Kersey, J, Chilcote, RR, Coccia, P, Exelby, P, Kushner, J, Siegel, S & Hammond, D 1983, 'Childhood Non-Hodgkin's Lymphoma: The Results of a Randomized Therapeutic Trial Comparing a 4-Drug Regimen (Comp) with a 10-Drug Regimen (Lsa2-L2)', New England Journal of Medicine, vol. 308, no. 10, pp. 559-565. https://doi.org/10.1056/NEJM198303103081003
Anderson, James R. ; Wilson, John F. ; Jenkin, R. Derek T. ; Meadows, Anna T. ; Kersey, John ; Chilcote, Robert R. ; Coccia, Peter ; Exelby, Philip ; Kushner, Joseph ; Siegel, Stuart ; Hammond, Denman. / Childhood Non-Hodgkin's Lymphoma : The Results of a Randomized Therapeutic Trial Comparing a 4-Drug Regimen (Comp) with a 10-Drug Regimen (Lsa2-L2). In: New England Journal of Medicine. 1983 ; Vol. 308, No. 10. pp. 559-565.
@article{61755f929a104798b2f1ffb84535f4a2,
title = "Childhood Non-Hodgkin's Lymphoma: The Results of a Randomized Therapeutic Trial Comparing a 4-Drug Regimen (Comp) with a 10-Drug Regimen (Lsa2-L2)",
abstract = "Members of the Childrens Cancer Study Group treated 234 eligible patients in a randomized trial designed to study the relative effectiveness of two therapy programs for the treatment of childhood and adolescent non-Hodgkin's lymphoma. Two chemotherapeutic strategies were compared: a 4-drug regimen (COMP) and a 10-drug regimen (modified LSA2-L2). Failure-free survival for all patients was 60 per cent at 24 months. In patients with disseminated disease treatment success was influenced by both the histologic subtype of disease and the therapeutic regimen followed. The 10-drug program was more effective than the 4-drug program in patients with disseminated lymphoblastic disease (two-year failure-free survival rate, 76 vs. 26 per cent, respectively; P = 0.0002), whereas the 4-drug program was more effective than the 10-drug program in those with nonlymphoblastic disease (57 vs. 28 per cent, respectively, P = 0.008). The less toxic, more easily administered 4-drug regimen was as effective as the 10-drug regimen in patients with localized disease (89 vs. 84 per cent, respectively). (N Engl J Med. 1983; 308:559–65.) Considerable progress was made during the 1960s in the treatment of some pediatric cancers — most notably, Wilms' tumor and acute lymphoblastic leukemia. This was not true for the non-Hodgkin's lymphomas of childhood. During the 1960s, only 15 per cent of children with non-Hodgkin's lymphoma could be expected to survive longer than two years.1 The first indications that the use of multiagent therapy could control disease over the long term came from Djerassi and Kim, who obtained promising results with intravenous methotrexate combined with other agents2; from Ziegler, who reported long-term disease control in both American and African patients.",
author = "Anderson, {James R.} and Wilson, {John F.} and Jenkin, {R. Derek T.} and Meadows, {Anna T.} and John Kersey and Chilcote, {Robert R.} and Peter Coccia and Philip Exelby and Joseph Kushner and Stuart Siegel and Denman Hammond",
year = "1983",
month = "3",
day = "10",
doi = "10.1056/NEJM198303103081003",
language = "English (US)",
volume = "308",
pages = "559--565",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "10",

}

TY - JOUR

T1 - Childhood Non-Hodgkin's Lymphoma

T2 - The Results of a Randomized Therapeutic Trial Comparing a 4-Drug Regimen (Comp) with a 10-Drug Regimen (Lsa2-L2)

AU - Anderson, James R.

AU - Wilson, John F.

AU - Jenkin, R. Derek T.

AU - Meadows, Anna T.

AU - Kersey, John

AU - Chilcote, Robert R.

AU - Coccia, Peter

AU - Exelby, Philip

AU - Kushner, Joseph

AU - Siegel, Stuart

AU - Hammond, Denman

PY - 1983/3/10

Y1 - 1983/3/10

N2 - Members of the Childrens Cancer Study Group treated 234 eligible patients in a randomized trial designed to study the relative effectiveness of two therapy programs for the treatment of childhood and adolescent non-Hodgkin's lymphoma. Two chemotherapeutic strategies were compared: a 4-drug regimen (COMP) and a 10-drug regimen (modified LSA2-L2). Failure-free survival for all patients was 60 per cent at 24 months. In patients with disseminated disease treatment success was influenced by both the histologic subtype of disease and the therapeutic regimen followed. The 10-drug program was more effective than the 4-drug program in patients with disseminated lymphoblastic disease (two-year failure-free survival rate, 76 vs. 26 per cent, respectively; P = 0.0002), whereas the 4-drug program was more effective than the 10-drug program in those with nonlymphoblastic disease (57 vs. 28 per cent, respectively, P = 0.008). The less toxic, more easily administered 4-drug regimen was as effective as the 10-drug regimen in patients with localized disease (89 vs. 84 per cent, respectively). (N Engl J Med. 1983; 308:559–65.) Considerable progress was made during the 1960s in the treatment of some pediatric cancers — most notably, Wilms' tumor and acute lymphoblastic leukemia. This was not true for the non-Hodgkin's lymphomas of childhood. During the 1960s, only 15 per cent of children with non-Hodgkin's lymphoma could be expected to survive longer than two years.1 The first indications that the use of multiagent therapy could control disease over the long term came from Djerassi and Kim, who obtained promising results with intravenous methotrexate combined with other agents2; from Ziegler, who reported long-term disease control in both American and African patients.

AB - Members of the Childrens Cancer Study Group treated 234 eligible patients in a randomized trial designed to study the relative effectiveness of two therapy programs for the treatment of childhood and adolescent non-Hodgkin's lymphoma. Two chemotherapeutic strategies were compared: a 4-drug regimen (COMP) and a 10-drug regimen (modified LSA2-L2). Failure-free survival for all patients was 60 per cent at 24 months. In patients with disseminated disease treatment success was influenced by both the histologic subtype of disease and the therapeutic regimen followed. The 10-drug program was more effective than the 4-drug program in patients with disseminated lymphoblastic disease (two-year failure-free survival rate, 76 vs. 26 per cent, respectively; P = 0.0002), whereas the 4-drug program was more effective than the 10-drug program in those with nonlymphoblastic disease (57 vs. 28 per cent, respectively, P = 0.008). The less toxic, more easily administered 4-drug regimen was as effective as the 10-drug regimen in patients with localized disease (89 vs. 84 per cent, respectively). (N Engl J Med. 1983; 308:559–65.) Considerable progress was made during the 1960s in the treatment of some pediatric cancers — most notably, Wilms' tumor and acute lymphoblastic leukemia. This was not true for the non-Hodgkin's lymphomas of childhood. During the 1960s, only 15 per cent of children with non-Hodgkin's lymphoma could be expected to survive longer than two years.1 The first indications that the use of multiagent therapy could control disease over the long term came from Djerassi and Kim, who obtained promising results with intravenous methotrexate combined with other agents2; from Ziegler, who reported long-term disease control in both American and African patients.

UR - http://www.scopus.com/inward/record.url?scp=0020658320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020658320&partnerID=8YFLogxK

U2 - 10.1056/NEJM198303103081003

DO - 10.1056/NEJM198303103081003

M3 - Article

C2 - 6338381

AN - SCOPUS:0020658320

VL - 308

SP - 559

EP - 565

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 10

ER -